Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00907101 · ClinicalTrials.gov registry record · Phase 4
Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes
A Phase 4 study of P Acnes Colonization, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00907101 is a Phase 4 study of P Acnes Colonization that has completed, run by Galderma R&D. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00907101, a Phase 4 study of P Acnes Colonization, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effectiveness of Epiduo® Gel in reducing antibiotic sensitive and resistant strains of P acnes in vivo.
Conditions Studied
Interventions
- DRUG Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)
Study Locations (1)
Pennsylvania
- Skin Study Center - Broomall
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-06 |
| Est. Completion | 2009-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00907101
The ClinicalTrials.gov registry entry for NCT00907101 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with P Acnes Colonization appearing as the primary indexed condition, and to 1 intervention - of which Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel) is the first listed.
NCT00907101 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00907101 about?
NCT00907101 is a clinical study titled "Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes". The purpose of this study is to evaluate the effectiveness of Epiduo® Gel in reducing antibiotic sensitive and resistant strains of P acnes in vivo.
What is the current status of trial NCT00907101?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2009-06. Estimated completion is 2009-07.
What conditions does trial NCT00907101 study?
This clinical trial studies the following conditions: P Acnes Colonization.
What interventions are being tested in trial NCT00907101?
The interventions under investigation include: Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel) (DRUG).
Who is sponsoring clinical trial NCT00907101?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00907101 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.